References
- Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters Biostatistics. Biostatistics (Oxford, England). 2019 Apr 1;20(2):273–286.
- Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products
- Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts ‘similar medicinal product’ and clinical superiority.
- EMA Annual report on the use of the special contribution for orphan medicinal products Year 2020, 2021 Feb 15, available at: EMA/30719/2021, https://www.ema.europa.eu/en/documents/report/annual-report-use-special-contribution-orphan-medicinal-products-2020_en.pdf
- Nicod E, Whittal A, Drummond M, et al., Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches. Orphanet J Rare Dis. 2020;15(1):189.
- Republique Française, Article L.601-2 (new article L.5121-12) created by the 21st article of the law no 92-1279 of December 8th, 1992, French public health code. J Officiel de la Republique Française. 1992 Dec 11;288:16888.
- Republique Française, Articles R5142-20 to R5142-30 created par the decree no 94-568 of July 8th, 1994, French public health code. J Officiel de la Republique Française. 1994 Jul 10;159:9981.
- Agence nationale de securite du medicament et des produits de sante’ (ANSM). [cited 2021 Nov 26]. Available from: https://ansm.sante.fr
- French Social Security law of 14th December 2020 (Article 78- La Loi de financement de la sécurité sociale, FSSL) for the healthcare plan of 2021.
- Law n. 648, 1996 Dec 23 (Gazzetta Ufficiale n.300 of 23 December 1996)
- Law n. 326, 2003 Nov 24 (Gazzetta Ufficiale n. 274 of 25 November 2003 - Suppl. Ordinario n. 181)
- D.L. 158/2012, art. 12, comma 5-bis, c.m. L. 189/2012 (Gazzetta Ufficiale n.214 del 13-09-2012)
- Federal Joint Committee (G-BA) [cited 2021 Nov 26]. Available from: https://www.g-ba.de/
- Institut national d’assurance maladie-invalidité (INAMI). [cited 2021 Nov 26]. Available from: https://www.inami.fgov.be
- The Danish Medicines Council. [cited 2021 Nov 26]. Available from: https://medicinraadet.dk/om-os
- National Health Care Institute (ZIN). [cited 2021 Nov 26]. Available from: http://www.zorginstituutnederland.nl/
- Norwegian Medicines Agency (NOMA). [cited 2021 Nov 26]. Available from: https://legemiddelverket.no
- NICE highly specialised technologies guidance [cited 2021 Nov 26]. Available from: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-highly-specialised-technologies-guidance
- de Varax A, Letellier M, Börtlein G. Study on orphan drugs: phase I: overview of the conditions for marketing orphan drugs in Europe. Paris: Alcimed; 2015. p. 2004.
- Garau M, Mestre-Ferrandiz J, 2009. Access mechanisms for orphan drugs: a comparative study of selected European countries. [cited 2021 Nov 26]. Available from: https://www.ohe.org/publications/access-mechanisms-orphan-drugs-comparative-study-selected-european-countries#
- Sarnola K, Ahonen R, Martikainen JE, et al. Policies and availability of orphan medicines in outpatient care in 24 European countries. Eur J Clin Pharmacol. 2018 Jul;74(7):895–902.
- Malinowski KP, Kawalec P, Trabka W, et al. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment. Front Pharmacol. 2018;12(9):1263.
- Pejcic AV, Iskrov G, Jakovljevic MM, et al. Access to orphan drugs - comparison across Balkan countries. Health Policy. 2018;122(6):583–589.
- Heard JM, Vrinten C, Schlander M, et al. MetabERN collaboration group. Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network. Orphanet J Rare Dis. 2020;15(1):3.
- Detiček A, Locatelli I, Kos M. Patient access to medicines for rare diseases in European countries. Value Health. 2018;21(5):553–560.
- Zamora B, Maignen F, O’Neill P, et al. Comparing access to orphan medicinal products in Europe. Orphanet J Rare Dis. 2019 May 3;14(1):95.
- The European Federation of Pharmaceutical Industries and Associations (EFPIA). EFPIA Patient W.A.I.T. 2020 Survey (April 2021). [cited 2021 Nov 26]. Available from: https://www.efpia.eu/media/602652/efpia-patient-wait-indicator-final-250521.pdf
- European Commission. Joint evaluation of Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Brussels, 2020 Aug 11, https://ec.europa.eu/health/sites/default/files/files/paediatrics/docs/orphan-regulation_eval_swd_2020-163_part-1.pdf
- EFPIA. The root cause of unavailability and delay to innovative medicines (June 2020) [cited 2021 Nov 26]. Available from: https://www.efpia.eu/media/602653/root-cause-unavailability-delays-cra-report-may-2021-final.pdf
- Garrido MV, Mangiapane S. Surrogate outcomes in health technology assessment: an international comparison. Int J Technol Assess Health Care. 2009;25(3):315–322.
- Ciani O, Buyse M, Drummond M, et al. Time to review the role of surrogate end points in health policy: state of the art and the way forward. Value Health. 2017;20(3):487–495.
- Ciani O, Grigore B, Blommestein H, et al. Validity of surrogate endpoints and their impact on coverage recommendations: a retrospective analysis across International Health Technology Assessment Agencies. Med Decis Making. 2021;41(4):439–452.
- Tafuri G, Pagnini M, Moseley J, et al. How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice. Br J Clin Pharmacol. 2016 Oct;82(4):965–973.
- Vreman RA, de Ruijter AS, Zawada A, et al. Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations. Drug Discov Today. 2020 Jul;25(7):1223–1231.
- Proposal for a Regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU. Brussels, 2018 Jan 31.
- European Council of the European Union. Press Release 2021 Dec 13, https://ec.europa.eu/commission/presscorner/detail/en/ip_21_6771
- The Beneluxa Initiative [cited 2021 Nov 26]. Available from: https://beneluxa.org/
- Beneluxa Review Group Assessment Summary (April 2021), available at: http://www.ncpe.ie/wp-content/uploads/2020/05/Executive-summary-Zolgensma-Beneluxa-IrelandFinal-Version.pdf
- European Commission. Health Technology Assessment Sharing Experiences from the Regional Cooperations: high Level Summary 2018. [cited 2021 Nov 26]. Available from: https://ec.europa.eu/health/sites/default/files/technology_assessment/docs/2018_regional_hta_reportsum_en.pdf
- Eatwell E, Swierczyna A Emerging voluntary cooperation between European healthcare systems: are we facing a new future? Medicine Access @ Point of Care. 2019.
- Regulation (EC) no 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products.
- [cited 2021 Nov 26]. Available from:https://www.cnbc.com/2019/05/24/fda-approves-novartis-2-million-spinal-muscular-atrophy-gene-therapy.html
- EvaluatePharma Orphan Drug Report [cited 2021 Nov 26]. Available from: 2020, https://www.evaluate.com/orphan-drugs
- Berdud M, Drummond M, Towse A. Establishing a reasonable price for an orphan drug. Cost Eff Resour Alloc. 2020;18(1):31.
- Sussex J, Rollet P, Garau M, et al. A pilot study of multicriteria decision analysis for valuing orphan medicines. Value Health. 2013;16(8):1163–1169.
- Henderson N, Errea M, Skedgel C, et al. Ethical and economic issues in the appraisal of medicines for ultra-rare conditions. OHE Consulting Report. Jan 2020. https://www.ohe.org/publications/ethical-and-economic-issues-appraisal-medicines-ultra-rare-conditions-0
- National Institute for Health and Care Excellence, Nusinersen for treating spinal muscular atrophy. Technology appraisal guidance [TA588]. Published: 2019 Jul 24, https://www.nice.org.uk/guidance/ta588
- Whittal A, Nicod E, Drummond M, et al. Examining the impact of different country processes for appraising rare disease treatments: a case study analysis. Int J Technol Assess Health Care. 2021 May 28;37(1):e65.
- Schlander M, Garattini S, Kolominsky-Rabas P, et al. Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement. J Mark Access Health Policy. 2016;4 :33039 .
- Fortinguerra F, Tafuri G, Trotta F, et al. Using GRADE methodology to assess innovation of new medicinal products in Italy. Br J Clin Pharmacol. 2020 Jan;86(1):93–105.
- Wenzl M, Chapman S. 2019. Performance-based managed entry agreements for new medicines in OECD countries and EU member states: how they work and possible improvements going forward. OECD Health Working Papers, No. 115, OECD Publishing, Paris. DOI:https://doi.org/10.1787/6e5e4c0f-en
- Villa F, Tutone M, Altamura G, et al. Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency. Health Policy. 2019;123(6):595–600.
- Jørgensen J, Hanna E, Kefalas P. Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries. J Mark Access Health Policy. 2020 Jan 15;8(1):1715536.
- [cited 2021 Nov 26]. Available from:https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-access-contract-denmark-current-and-future
- [cited 2021 Nov 26]. Available from:https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-agreement-nhs-england-access-all-licensed
- [cited 2021 Nov 26]. Available from:https://investors.vrtx.com/news-releases/news-release-details/vertex-and-republic-ireland-expand-long-term-cystic-fibrosis
- World Health Assembly (WHA) Resolution WHA72.8: improving the transparency of markets for medicines, vaccines, and other health products. [cited 2021 Nov 26]. Available from: Geneva: World Health Assembly, 72 2019. https://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_R8-en.pdf
- Rintoul A, Colbert A, Garner S, et al. Medicines with one seller and many buyers: strategies to increase the power of the payer. BMJ. 2020;369:1705.
- Russo P, Carletto A, Németh G, et al. Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey. Health Policy. 2021;125(9):1140–1145.
- Vogler S, Paterson KR. Can price transparency contribute to more affordable patient access to medicines? PharmacoEcon Open. 2017;1(3):145–147.
- Mendoza RL. Incentives and disincentives to drug innovation: evidence from recent literature. J Med Econ. 2019;22(8):713–721.
- Ahmad NS, Makmor-Bakry M, Hatah E. Drug price transparency initiative: a scoping review. Res Social Adm Pharm. 2020;16(10):1359–1369.
- Crisafulli S, Sultana J, Ingrasciotta Y, et al. Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study. Expert Opin Drug Saf. 2019;18(6):497–509.
- Hampson G, Towse A, Dreitlein WB, et al. Real-world evidence for coverage decisions: opportunities and challenges. J Comp Eff Res. 2018;7(12):1133–1143.
- INSERM. Rare disease registries in Europe. Orphanet Report Series. Rare Diseases Collection. [cited 2021 Nov 26]. Available from: May 2018. available at: www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf.
- EMA-EUnetHTA three-year work plan 2017–2021 [cited 2021 Nov 26]. Available from: https://www.ema.europa.eu/en/documents/other/ema-eunethta-work-plan-2017-2021_en.pdf
- Facey KM, Rannanheimo P, Batchelor L, et al. Real-world evidence to support Payer/HTA decisions about highly innovative technologies in the EU-actions for stakeholders. Int J Technol Assess Health Care. 2020;1–10. DOI:https://doi.org/10.1017/S026646232000063X.